We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
BIO-RAD LABORATORIES

Randox Laboratories

Provides global diagnostic solutions for hospital laboratories, forensic laboratories, research laboratories, pharmac... read more Featured Products: More products

Download Mobile App




New Supermix Controls to Streamline QC in Clinical Laboratories

By LabMedica International staff writers
Posted on 20 Mar 2014
Print article
Image: The two new liquid assayed quality controls from Randox are supermix combinations of multiple controls for streamlining QC in clinical laboratories (Photo courtesy of Randox).
Image: The two new liquid assayed quality controls from Randox are supermix combinations of multiple controls for streamlining QC in clinical laboratories (Photo courtesy of Randox).
Two new liquid assayed chemistry controls have been designed to streamline quality control (QC) by cutting the number of individual QCs a laboratory needs to run in routine medical testing, saving time and money while ensuring highly accurate results and patient diagnosis.

The two new controls, Acusera liquid assayed Liquid Chemistry Premium and Liquid Chemistry Premium Plus from Randox Laboratories (Antrim, North Ireland, UK), enable laboratories to run QC on up to 100 analytes all within one test, without compromising performance or accuracy. The concept of offering multianalyte controls is not new; however, these latest assayed controls from Randox are the most comprehensive on the world market to date, containing a unique supermix combination of proteins, lipids, immunoassays, cardiac markers, blood markers, therapeutic drugs, and routine chemistry analytes.

Available in 3 concentration levels (low, mid, and high), Premium Plus covers a very broad clinical range, removing the need for laboratories to purchase additional, often expensive, low or high level controls. The Acusera Liquid Chemistry Premium Plus control contains 100 analytes, while the Acusera "Liquid Chemistry Premium" control offers 91, with the following features. The high levels of CRP and other key proteins included eliminate the need for multiple controls, dramatically streamlining QC. They are assayed controls, providing clinically significant values for a wide range of analyzers at key decision points. Both controls are liquid for ease of use, eliminating possible reconstitution errors and improving lab efficiency. The controls are highly stable when stored at -20 °C to -70 °C, with open vial stability of up to 7 days at 2–8 °C, reducing wastage in laboratories. They are manufactured using human-based serum, ensuring performance that closely mirrors patient samples.

As true third party controls, laboratories are far better assured of unbiased, independent assessment of analytical performance and as such help deliver highly accurate results and patient diagnosis.

"These new assayed controls will be hugely beneficial to medical laboratories running a wide range of routine patient tests, allowing them to consolidate all or the majority of their QC within one control," said Dr. John Campbell, PhD. Steven Jordan, Randox’s Global Manager for QC, said, "Randox reputation as a leading global provider of quality controls takes another step forward with the launch of Acusera Liquid Chemistry Premium and Premium Plus. We’re delighted to be pushing the boundaries of quality control, helping laboratories improve their performance and productivity whilst ensuring highly accurate results and improving patient diagnosis."

The controls are now available in the UK, Europe, Middle East, Far East, and Africa. Randox is currently awaiting product approval from the US FDA and China SFDA.

Related Links:

Randox Laboratories
Acursera Liquid QC  


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Xylazine Immunoassay Test
Xylazine ELISA

Print article

Channels

Molecular Diagnostics

view channel
Image: AI analysis of DNA fragmentomes and protein biomarkers noninvasively detects ovarian cancer (Photo courtesy of Adobe Stock)

Blood-Based Machine Learning Assay Noninvasively Detects Ovarian Cancer

Ovarian cancer is one of the most common causes of cancer deaths among women and has a five-year survival rate of around 50%. The disease is particularly lethal because it often doesn't cause symptoms... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The groundbreaking treatment approach has shown promise in hard-to-treat cancers (Photo courtesy of 123RF)

Genetic Testing Combined With Personalized Drug Screening On Tumor Samples to Revolutionize Cancer Treatment

Cancer treatment typically adheres to a standard of care—established, statistically validated regimens that are effective for the majority of patients. However, the disease’s inherent variability means... Read more

Pathology

view channel
Image: The device can serve as a sample pretreatment tool for cytological diagnosis of malignant effusions (Photo courtesy of Microsystems & Nanoengineering: Zhu, Z., Ren, H., Wu, D. et al.)

Microfluidic Device for Cancer Detection Precisely Separates Tumor Entities

Tumor cell clusters are increasingly recognized as crucial in cancer pathophysiology, with growing evidence of their increased resistance to treatment and higher metastatic potential compared to single tumor cells.... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.